Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 13/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487605 | 0.88 | DRD4 (0.48) | DRD4KCNJ1ALDH1A1LMNAMAPT | |
| SCHEMBL4474051 | 0.88 | DRD4 (0.48) | DRD4KCNJ1ALDH1A1LMNAMAPT | |
| SCHEMBL5618649 | 0.88 | DRD4 (0.48) | DRD4KCNJ1ALDH1A1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL5618667 | 0.88 | DRD4 (0.48) | DRD4KCNJ1ALDH1A1LMNAMAPT | |
| SCHEMBL7023395 | 0.84 | DRD4 (0.48) | DRD4KCNJ1ALDH1A1LMNAMAPT | |
| SCHEMBL4492316 | 0.79 | DRD4 (0.42) | DRD4KCNJ1ALDH1A1LMNAMAPT | |
| SCHEMBL6669700 | 0.77 | DRD4 (0.50) | DRD4SIGMAR1LMNAKDM4E | |
| SCHEMBL4481888 | 0.74 | KCNJ1 (0.43) | DRD4KCNJ1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL4476568 | 0.71 | DRD4 (0.51) | DRD4KCNJ1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL6682343 | 0.71 | DRD4 (0.51) | DRD4KCNJ1SIGMAR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20060063765-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063765-A1 | Novel compounds | CCR3, NSUN3, CCR1 | DRD4 1757/4885KCNJ1 2059/4885SIGMAR1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.